Safety flags, transparency gaps, dosing concerns, and recurring buyer complaints.
Safety signals
Drug interaction risk — resveratrol
Inhibits CYP3A4, CYP2C9, and CYP2D6 at doses ≥1,000 mg/day (activates CYP1A2). Interacts with warfarin (increased anticoagulant effect), tamoxifen, statins (myopathy risk), tacrolimus, and NSAIDs/antiplatelets (bleeding risk).
Read more
Safety flag
resveratrol: CYP3A4 interactions
Dose or interaction risk detected. See ingredient page for details.
No public lab certificate
Certificate of Analysis not published
Without a public lab certificate, batch purity and potency cannot be independently verified.
No third-party testing
Independent lab verification not disclosed
The brand does not publish evidence of independent batch testing.
Low transparency
3.0/10 quality transparency
Limited public information about sourcing, testing, or manufacturing.